NCM · Biotechnology

VRAX (VRAX) Stock

$2.62 -6.43% NCM: VRAX Healthcare

Valuation

MetricValue
Price$2.62
Market Cap$488958
P/E Ratio-0.71
P/B Ratio0.21
P/S Ratio231.20
EPS (TTM)$-0.24
52-Week High$8.89
52-Week Low$0.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-83.82%
ROA-48.40%
ROCE-120.00%
Gross Margin—
Operating Margin—
Net Margin0.00%
Debt/Equity0.10
Current Ratio5.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-1.0M$-2.0M$-6.0M$-6.0M$-6.0M
Net Profit$-1.0M$-2.0M$-5.0M$-7.0M$-6.0M
EPS$-0.57$-1.50$-5.13$-3.36$-1.95
Op Margin-520.5%—-66963.7%-4153.3%-97344.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$0$0$10.0M$5.0M$6.0M
Total Liabilities$1.0M$1.0M$1.0M$0$1.0M
Cash$0$0$9.0M$4.0M$4.0M
Borrowings$0$0$0$0$0

Latest News

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement PR Newswire · Jul 16, 2026 Virax Biolabs enters immune profiling product supply deal with Fosun Hospital Management · Jul 13, 2026 Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds PR Newswire · Jul 10, 2026 Top Midday Decliners MT Newswires · Jul 10, 2026 Top Premarket Decliners MT Newswires · Jul 10, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-1.0M$-4.0M$-6.0M$-5.0M
Investing Cash Flow$0$0$-1.0M$-2.0M$-1.0M
Financing Cash Flow$1.0M$0$0$2.0M$1.0M
Net Cash Flow$0$0$9.0M$-6.0M$1.0M
Free Cash Flow$-1.0M$-1.0M$-4.0M$-7.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-7.11
EV / EBITDA—
FCF Yield-878.62%
Quick Ratio11.21
Interest Coverage—
Return 1Y-84.14%
Return 3Y-96.54%
Return 5Y—

Ownership

Insiders Held2.62%
Institutions Held4.61%
Institutions Float Held4.74%
Institutional HolderSharesReport Date
Armistice Capital, LLC35,1522026-03-31
Jump Financial, LLC1,6292026-03-31
Farther Finance Advisors, Llc12026-03-31
Osaic Holdings Inc.12026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARTL $0.77 +1.96% -0.12 $1.80M 0.00%
ATXIAvenue Therapeutics, Inc. $0.26 -32.94% -0.49 $856691 0.00%
DRMA $1.10 -0.90% -0.15 $749713 0.00%
ELAB $0.92 +2.21% 0.00 $1.78M 0.00%
GTBP $0.29 -4.65% -0.07 $3.12M 0.00%

About VRAX

VRAX is led by CEO James Foster, publicly traded since 2022.

VRAX stock trades at $2.62 with a market capitalization of $488958. The stock is valued at a price-to-earnings (P/E) ratio of -0.71, price-to-book of 0.21, price-to-sales of 231.20. Over the past 52 weeks the stock has ranged between $0.10 and $8.89, and currently trades 70.5% below its 52-week high.

On profitability, VRAX generates a return on equity (ROE) of -83.82%, return on capital employed of -120.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides